Intravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: Morbidity and mortality

Scandinavian Journal of Rheumatology

Volumn 37, Issue 2, 2008, Pages 130-134

  Goransson L G ^a,b   Brodin, C ^c   Ogreid P ^a   Janssen, E A M ^a   Romundstad, P R ^d   Vatten, L ^d   Wildhagen, K ^a   Kjellevold, K ^a   Omdal, R ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Sørlandet Hospital Health Enterprise   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MESNA;

ADULT; ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; BRAIN VASCULITIS; CANCER REGISTRY; CHRONIC INFLAMMATION; CHRONIC PATIENT; CHURG STRAUSS SYNDROME; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYSTOSCOPY; DRUG INDUCED CANCER; FEMALE; GIANT CELL ARTERITIS; GLOMERULONEPHRITIS; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; INFLAMMATORY DISEASE; LEUKOCYTOCLASTIC VASCULITIS; LUNG ALVEOLITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MICROSCOPIC POLYANGIITIS; MORBIDITY; MORTALITY; MYOSITIS; NORWAY; POLYARTERITIS NODOSA; POPULATION RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; STATISTICS; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULITIS; WEGENER GRANULOMATOSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; CYSTITIS; FEMALE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MESNA; MIDDLE AGED; NEOPLASMS; NORWAY; PROTECTIVE AGENTS; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; URINARY BLADDER NEOPLASMS;

EID: 42149097872     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701687234     Document Type: Article

References (20)

1. Boumpas DT, Austin HA 3rd, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
2. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomised, controlled trial. Ann Intern Med 1996;125:549-57.
3. Illei GG, Austin HA 3rd, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
4. McCune WJ, Fox D. Intravenous cyclophosphamide therapy of severe SLE. Rheum Dis Clin North Am 1989;15:455-77.
5. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegner granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
6. Guillevin L, Lhote F. Classification and management of necrotising vasculitides. Drugs 1997;53:805-16.
7. de Groot K, Adu D, Savage CO; EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001;16:2018-27.
8. Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 2006;46:124-30.
9. Valentini G, Paone C, La Montagna G, Chiarolanza I, Menegozzo M, Colutta E, et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 2006;35:35-8.
10. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84.
11. Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risk and relation to cyclophosphamide. Ann Rheum Dis 2004;63:1307-11.
12. Austin 3rd HA, Klippel JH, Balow JE, leRiche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-19.
13. Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 1991;42:781-95.
14. Rihova Z, Jancova E, Merta M, Zabka J, Rysava R, Bartunkova J, et al. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis - preliminary single center experience. Prague Med Rep 2004;105:64-8.
15. Houssiau FA. Cyclophosphamide in lupus nephritis. Lupus 2005;14:53-8.
16. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
17. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
18. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.
19. Omdal R, Husby G, Koldingsnes W. Intravenous and oral cyclophosphamide pulse therapy in rheumatic diseases: side effects and complications. Clin Exp Rheumatol 1993;11:283-8.
20. Shepherd JD, Pringle LE, Barnett MJ, Klingemann H-G, Reece DE, Phillips GL. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991;9:2016-20.